FY2024 Earnings Estimate for TRVI Issued By Leerink Partnrs

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Investment analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($0.49) per share for the year, down from their prior estimate of ($0.48). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.47) EPS and FY2026 earnings at ($0.45) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period last year, the company earned ($0.08) EPS.

TRVI has been the topic of a number of other research reports. Raymond James initiated coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a report on Friday, November 8th. B. Riley reissued a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, October 22nd. Finally, Leerink Partners assumed coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $7.43.

Trevi Therapeutics Trading Down 2.3 %

Shares of NASDAQ:TRVI opened at $3.00 on Monday. The stock has a market capitalization of $230.60 million, a PE ratio of -6.98 and a beta of 1.01. The firm has a 50 day moving average of $3.15 and a 200-day moving average of $2.91. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00.

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TRVI. Logos Global Management LP boosted its holdings in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after acquiring an additional 600,000 shares in the last quarter. Opaleye Management Inc. boosted its holdings in Trevi Therapeutics by 4.3% during the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock worth $9,125,000 after purchasing an additional 110,000 shares during the last quarter. Vanguard Group Inc. grew its position in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Trevi Therapeutics in the 2nd quarter worth about $4,395,000. Finally, Rosalind Advisors Inc. increased its stake in Trevi Therapeutics by 50.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after buying an additional 465,561 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Insider Activity at Trevi Therapeutics

In other news, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the transaction, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,255 shares of company stock worth $116,388 over the last ninety days. Insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.